Literature DB >> 2440422

Photoaffinity labelling of the cardiac calcium channel. (-)-[3H]azidopine labels a 165 kDa polypeptide, and evidence against a [3H]-1,4-dihydropyridine-isothiocyanate being a calcium-channel-specific affinity ligand.

D R Ferry, A Goll, H Glossmann.   

Abstract

The arylazide 1,4-dihydropyridine (-)-[3H]azidopine binds to a saturable population of sites in guinea-pig heart membranes with a dissociation constant (KD) of 30 +/- 7 pM and a density (Bmax.) of 670 +/- 97 fmol/mg of protein. This high-affinity binding site is assumed to reside on voltage-operated calcium channels because reversible binding is blocked stereoselectively by 1,4-dihydropyridine channel blockers and by the enantiomers of Bay K 8644. A low-affinity (KD 25 +/- 7 nM) high-capacity (Bmax. 21.6 +/- 9 pmol/mg of protein) site does not bind (-)- or (+)-Bay K 8644, but is blocked by high concentrations (greater than 500 nM) of dihydro-2,6-dimethyl-4-(2-isothiocyanatophenyl)-3,5-pyridinedicarboxy lic acid dimethyl ester (1,4-DHP-isothiocyanate) or, e.g., (+/-)-nicardipine. (-)-[3H]Azidopine was photoincorporated covalently into bands of 165 +/- 8, 39 +/- 2 and 35 +/- 3 kDa, as determined by SDS/polyacrylamide-gel electrophoresis. Labelling of the 165 kDa band is protected stereoselectively by 1,4-dihydropyridine enantiomers at low (nM) concentrations and by (-)- and (+)-Bay K 8644, whereas the lower-Mr bands are not. Thus, only the 165 kDa band is the calcium-channel-linked 1,4-dihydropyridine receptor. Photolabelling of the 39 or 35 kDa bands was only blocked by 10 microM-1,4-DHP-isothiocyanate or 50 microM-(+/-)-nicardipine but not by 10 microM-(-)-Bay K 8644. [3H]-1,4-DHP-isothiocyanate binds to guinea-pig heart membranes with a KD of 0.35 nM and dissociates with a k-1 of 0.2 min-1 at 30 degrees C. [3H]-1,4 DHP-isothiocyanate irreversibly labels bands of 39 and 35 kDa which are protected by greater than 10 microM-(+/-)-nicardipine or unlabelled ligand but not by 10 microM-(-)-Bay K 8644. Thus, [3H]-1,4-DHP-isothiocyanate is not an affinity probe for the calcium channel.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2440422      PMCID: PMC1147823          DOI: 10.1042/bj2430127

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  34 in total

1.  Studies on a new 1,5-benzothiazepine derivative (CRD-401). 3. Effects of optical isomers of CRD-401 on smooth muscle and other pharmacological properties.

Authors:  T Nagao; M Sato; Y Iwasawa; T Takada; R Ishida
Journal:  Jpn J Pharmacol       Date:  1972-08

2.  Determination of the molecular size of the nitrendipine-sensitive Ca2+ channel by radiation inactivation.

Authors:  R I Norman; M Borsotto; M Fosset; M Lazdunski; J C Ellory
Journal:  Biochem Biophys Res Commun       Date:  1983-03-29       Impact factor: 3.575

3.  Calculating the dissociation constant of an unlabeled compound from the concentration required to displace radiolabel binding by 50%.

Authors:  J Linden
Journal:  J Cyclic Nucleotide Res       Date:  1982

4.  Effects of unsymmetrical ester substituted 1,4-dihydropyridine derivatives and their optical isomers on contraction of smooth muscle.

Authors:  R Towart; E Wehinger; H Meyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-09       Impact factor: 3.000

5.  Evidence of multiple receptor sites within the putative calcium channel.

Authors:  D R Ferry; H Glossmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-10       Impact factor: 3.000

6.  Characterization of [3H]nifedipine binding sites in rabbit myocardium.

Authors:  M Holck; S Thorens; G Haeusler
Journal:  Eur J Pharmacol       Date:  1982-12-03       Impact factor: 4.432

7.  [3H]-Nitrendipine, a potent calcium antagonist, binds with high affinity to cardiac membranes.

Authors:  P Bellemann; D Ferry; F Lübbecke; H Glossman
Journal:  Arzneimittelforschung       Date:  1981

8.  Stereoselectivity at the calcium channel: opposite action of the enantiomers of a 1,4-dihydropyridine.

Authors:  R P Hof; U T Rüegg; A Hof; A Vogel
Journal:  J Cardiovasc Pharmacol       Date:  1985 Jul-Aug       Impact factor: 3.105

9.  Characterization of binding of the Ca++ channel antagonist, [3H]nitrendipine, to guinea-pig ileal smooth muscle.

Authors:  G T Bolger; P Gengo; R Klockowski; E Luchowski; H Siegel; R A Janis; A M Triggle; D J Triggle
Journal:  J Pharmacol Exp Ther       Date:  1983-05       Impact factor: 4.030

10.  The binding of [3H]nitrendipine to receptors for calcium channel antagonists in the heart, cerebral cortex, and ileum of rats.

Authors:  F J Ehlert; W R Roeske; E Itoga; H I Yamamura
Journal:  Life Sci       Date:  1982-06-21       Impact factor: 5.037

View more
  5 in total

Review 1.  Molecular basis of drug interaction with L-type Ca2+ channels.

Authors:  J Mitterdorfer; M Grabner; R L Kraus; S Hering; H Prinz; H Glossmann; J Striessnig
Journal:  J Bioenerg Biomembr       Date:  1998-08       Impact factor: 2.945

Review 2.  Calcium channels: molecular pharmacology, structure and regulation.

Authors:  M M Hosey; M Lazdunski
Journal:  J Membr Biol       Date:  1988-09       Impact factor: 1.843

3.  Photoaffinity-labelling of the calcium-channel-associated 1,4-dihydropyridine and phenylalkylamine receptor in guinea-pig hippocampus. A 195 kDa polypeptide carries both drug receptors and has similarities to the alpha 1 subunit of the purified skeletal-muscle calcium channel.

Authors:  J Striessnig; H G Knaus; H Glossmann
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

4.  A novel 1,4-dihydropyridine-binding site on mitochondrial membranes from guinea-pig heart, liver and kidney.

Authors:  G Zernig; H Glossmann
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

5.  Evidence for a distinct Ca2+ antagonist receptor for the novel benzothiazinone compound HOE 166.

Authors:  J Striessnig; E Meusburger; M Grabner; H G Knaus; H Glossmann; J Kaiser; B Schölkens; R Becker; W Linz; R Henning
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-03       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.